347P Chemotherapy (CT) and GnRH analogue (a) benefit in patients (pts)≤50 years (y) with estrogen receptor-positive (ER+)/HER2-negative (-) stage I–II breast cancer (BC) risk-stratified by Prosigna
F. Schettini(Breast Cancer Research Foundation), G Grazia(Breast Cancer Research Foundation), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Grazia Arpino(University of Naples Federico II), A. Caltavituro(Federico II University Hospital), Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), A. Musolino(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Michela Palleschi(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Vincenzo Di Lauro(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Benjamín Walbaum, Darío Sánchez(Hospital Universitario La Paz), TR Zatta, D. Morchón Araujo(Universidad de Salamanca), C.A.A. Rodríguez Sánchez(Universidad de Salamanca), A. López Paradís, M.A. Bergamino(Hospital Clínic de Barcelona)
Cited by 0
Related Papers
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance
|Endocrine Reviews|2008|545
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
|Cardiovascular Diabetology|2021|368
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype
|Cancer Treatment Reviews|2018|282